Quick Takeaways
- Gallant announced that its canine osteoarthritis (OA) mesenchymal stromal cell (MSC) therapy program has been granted eligibility for the US FDA Center for Veterinary Medicine’s expanded conditional approval pathway, with conditional approval targeted for 2028 for both canine and feline OA indications.
- In a randomized, placebo-controlled pilot study involving 88 client-owned dogs with naturally occurring OA, Gallant’s IV administered donor-derived UMSC therapy demonstrated statistically significant improvements in mobility, pain, and quality of life at Days 60 and 90 based on validated pet parent-reported outcomes, with no treatment-related serious adverse events observed.
- Gallant’s ready-to-use MSC therapy is designed for simple IV administration, eliminating the need for intra-articular injections, anesthesia, or specialist procedures typically associated with cell therapy for OA. The approach targets the inflammatory and immune pathways underlying osteoarthritis progression and is intended to make regenerative treatment more accessible across general veterinary practices.
Why It Matters?
Gallant is on track to create one of the first mass‑market, disease‑modifying OA biologics in companion animals, shifting regenerative medicine from niche referral centers into everyday general practice via a simple, ready‑to‑use IV product.
If conditional approval lands around 2028 for both dogs and cats, this could carve out a new premium OA segment that competes less with NSAIDs and more with long‑acting injectables and surgery, while setting a regulatory and commercial template for other stem‑cell and gene therapies in veterinary orthopedics and chronic pain.
Source: PRnewswire
